Regeneron Pharmaceuticals Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Regeneron Pharmaceuticals şirketinin temettü ödeme geçmişi bulunmamaktadır.

Anahtar bilgiler

n/a

Temettü verimi

1.8%

Geri Alım Getirisi

Toplam Hissedar Getirisi	1.8%
Gelecekteki Temettü Verimi	0%
Temettü Büyümesi	n/a
Bir sonraki temettü ödeme tarihi	n/a
Eski temettü tarihi	n/a
Hisse başına temettü	n/a
Ödeme oranı	n/a

Son temettü ve geri alım güncellemeleri

Recent updates

Ödemelerde İstikrar ve Büyüme

Temettü verilerini getirme

İstikrarlı Temettü: 0R2M şirketinin hisse başına düşen temettülerinin geçmişte istikrarlı olup olmadığını belirlemek için yeterli veri yok.

Büyüyen Temettü: 0R2M şirketinin temettü ödemelerinin artıp artmadığını belirlemek için yeterli veri yok.

Piyasaya Karşı Temettü Getirisi

Regeneron Pharmaceuticals Piyasaya Karşı Temettü Getirisi

0R2M temettü verimi piyasa ile karşılaştırıldığında nasıldır?
Segment	Temettü Verimi
Şirket (0R2M)	n/a
Pazarın Alt %25'i (GB)	2.1%
Pazarın En İyi %25'i (GB)	5.9%
Sektör Ortalaması (Biotechs)	1.6%
Analist tahmini (0R2M) (3 yıla kadar)	0%

Önemli Temettü: 0R2M şirketinin temettü getirisi, şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, temettü ödeyenlerin en alttaki %25'lik dilimine göre değerlendirilemiyor.

Yüksek Temettü: Şirketin yakın zamanda herhangi bir ödeme bildirmemesi nedeniyle, 0R2M şirketinin temettü getirisi, temettü ödeyenlerin en üst %25'ine göre değerlendirilemiyor.

Hissedarlara Ödenen Kazanç

Kazanç Kapsamı: 0R2M şirketinin temettü ödemelerinin kazançlarla karşılanıp karşılanmadığını belirlemek için ödeme oranını hesaplamak üzere yeterli veri yok.

Hissedarlara Nakit Ödeme

Nakit Akışı Kapsamı: 0R2M herhangi bir ödeme bildirmediğinden temettülerin sürdürülebilirliği hesaplanamıyor.

Regeneron Pharmaceuticals Temettüler ve Geri Alımlar

Temettü kriter kontrolleri 0/6

Anahtar bilgiler

Son temettü ve geri alım güncellemeleri

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

Recent updates

Regeneron Pharmaceuticals, Inc. to Present Hematology Pipeline Data At Ash 2024 Annual Meeting

Regeneron Pharmaceuticals, Inc. and Sanofi Receive European Union Approval For Dupixent In Young Children With Eosinophilic Esophagitis

Third quarter 2024 earnings released: EPS: US$12.40 (vs US$9.48 in 3Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Three-Year (156-Week) Data for EYLEA HD® (Aflibercept) Injection 8 mg from an Extension Study of the Phase 3 PHOTON Trial in Patients with Diabetic Macular Edem

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. and Sanofi Announce National Medical Products Administration Approves Dupixent in China

Regeneron Pharmaceuticals, Inc. to Report Q3, 2024 Results on Oct 31, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Approves Dupixent (Dupilumab) as First and Only Treatment for Adolescents with Chronic Rhinosinusitis with Nasal Polyps

Senior VP of Finance & CFO recently sold US$6.4m worth of stock

Regeneron Pharmaceuticals, Inc Announces Ordspono (odronextamab) Approved in the European Union for the Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma

Regeneron Provides Update on Biologics License Application for Linvoseltamab

Insider recently sold US$5.6m worth of stock

Second quarter 2024 earnings released: EPS: US$13.25 (vs US$9.05 in 2Q 2023)

Regeneron Pharmaceuticals, Inc. and Sanofi Announces Approval in the European Union as the First-Ever Targeted Therapy for Patients with COPD

Regeneron Pharmaceuticals, Inc. Announces Odronextamab Recommended for EU Approval by the CHMP to Treat Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma

Regeneron Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 01, 2024

Regeneron Pharmaceuticals, Inc Announces Dupixent® (dupilumab) Positive Phase 3 Data in Children 1 to 11 Years of Age with Eosinophilic Esophagitis Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. Announces 14-Month Median Follow-Up Data from the Pivotal Phase 1/2 Linker-MM1 Trial of Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc and Sanofi Announces Update on FDA Priority Review of Dupixent® (dupilumab) for the Treatment of COPD Patients with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Positive New Results from an Ongoing Phase 1/2 Trial Evaluating its First-in-Class Costimulatory Bispecific Antibody, REGN7075 (EGFRxCD28)

Regeneron Pharmaceuticals, Inc. and Sanofi Presents Late-Breaking Data from NOTUS Confirmatory Phase 3 COPD Trial Presented at ATS and Published in the New England Journal of Medicine

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts for Priority Review the Supplemental Biologics License Application (sBLA) for Dupixent

Regeneron Pharmaceuticals, Inc. Announces Latest DB-OTO Results Show Dramatically Improved Hearing to Normal Levels in a Child with Profound Genetic Deafness Within 24 Weeks and Initial Hearing Improvements in a Second Child at 6 Weeks

New minor risk - Shareholder dilution

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) announces an Equity Buyback for $3,000 million worth of its shares.

First quarter 2024 earnings released: EPS: US$6.70 (vs US$7.64 in 1Q 2023)

Regeneron Pharmaceuticals, Inc. Announces Positive Pivotal Data from the Phase 1/2 LINKER-MM1 Trial of Linvoseltamab in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc., Annual General Meeting, Jun 14, 2024

Regeneron Pharmaceuticals, Inc. (NasdaqGS:REGN) completed the acquiistion of R&D pipeline from 2seventy bio, Inc. (NasdaqGS:TSVT) for $20 million.

Regeneron Pharmaceuticals, Inc Provides Update on Biologics License Application for Odronextamab

Regeneron Pharmaceuticals, Inc.'s Praluent® (alirocumab) Injection Receives FDA Approval to Treat Children with Genetic Form of High Cholesterol

Regeneron Pharmaceuticals, Inc. Announces the Lancet Published One-Year Results from the Pivotal Pulsar and Photon Trials for EYLEA HD (Aflibercept) Injection 8 Mg

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepts Dupixent®? (Dupilumab) Sbla for Treatment of Copd with Type 2 Inflammation

Regeneron Pharmaceuticals, Inc. Announces Linvoseltamab BLA for Treatment of Relapsed/Refractory Multiple Myeloma Accepted for FDA Priority Review

Regeneron Pharmaceuticals, Inc. and Sanofi Announces the Ministry of Health, Labor and Welfare in Japan Grants Marketing and Manufacturing Authorization for Dupixent (Dupilumab) for the Treatment of Chronic Spontaneous Urticaria

Insider recently sold US$7.6m worth of stock

Full year 2023 earnings released: EPS: US$37.05 (vs US$40.51 in FY 2022)

Regeneron Pharmaceuticals, Inc. Receives EMA Filing Acceptance for Treatment of Relapsed/Refractory Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Appoints Jason Pitofsky as Controller, Expects to Occur on February 5, 2024

Regeneron Pharmaceuticals, Inc. and Sanofi Announce That U.S. Food and Drug Administration Approves Dupixent®? (Dupilumab) for the Treatment of Children Aged 1 Year and Older with Eosinophilic Esophagitis

Regeneron Pharmaceuticals, Inc. and Sanofi Announce U.S. Food and Drug Administration Updates the Label for Dupixent (Dpilumab)

Regeneron Pharmaceuticals, Inc. to Report Q4, 2023 Results on Feb 02, 2024

Regeneron Pharmaceuticals, Inc. Announces New and Updated Data for Odronextamab in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma Pivotal Trial Showed Deep and the Potential of ctDNA to Predict Long-Term Outcomes

Regeneron Pharmaceuticals, Inc. Announces Updated Linvoseltamab Pivotal Data Demonstrated Strong Rates and Depth of Response in Patients with Heavily Pre-Treated Multiple Myeloma

Regeneron Pharmaceuticals, Inc. Announces Presentation of New and Updated Data on Multiple Combination Therapies from its Oncology Pipeline at ESMO IO Congress 2023

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Regeneron Pharmaceuticals, Inc. Announces the Second Dupixent (Dupilumab) Investigational Phase 3 Chronic Obstructive Pulmonary Disease (COPD) Trial

Third quarter 2023 earnings released: EPS: US$9.48 (vs US$12.31 in 3Q 2022)

Regeneron Pharmaceuticals, Inc. Announces Long-Term Outcomes and New Analyses of Pivotal Clinical Data for EYLEA®? HD (aflibercept) Injection 8mg

Regeneron Pharmaceuticals, Inc. Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

Regeneron Pharmaceuticals, Inc. and Sanofi Provide Update on Dupixent®? (Dupilumab) sBLA for Chronic Spontaneous Urticaria

Regeneron Pharmaceuticals, Inc. Announces Clinical Data from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

Regeneron Pharmaceuticals, Inc. Announces the First Presentation of Positive Two-Year Results from the Pivotal Pivotal Pulsar Trial Investigating Eylea Hd (Aflibercept) Injection 8 Mg with 12-Week Dosing Regimens

Regeneron Pharmaceuticals, Inc. Announces U.S. Food and Drug Administration Accepts Odronextamab BLA for Treatment of Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-Cell Lymphoma for Priority Review

Regeneron Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 02, 2023

Regeneron Pharmaceuticals, Inc. and Sanofi Announces U.S. Food and Drug Administration Accepted for Priority Review

Ödemelerde İstikrar ve Büyüme

Piyasaya Karşı Temettü Getirisi

Hissedarlara Ödenen Kazanç

Hissedarlara Nakit Ödeme

Güçlü temettü ödeyen şirketleri keşfedin